Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

November 21, 2019

Study Completion Date

May 24, 2023

Conditions
Malignant Solid Neoplasm
Interventions
DRUG

Ferumoxytol

Given IV

DRUG

Irinotecan Sucrosofate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Veliparib

Given PO

Trial Locations (6)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

20892

National Institutes of Health Clinical Center, Bethesda

NCI - Center for Cancer Research, Bethesda

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

44195

Cleveland Clinic Foundation, Cleveland

55905

Mayo Clinic in Rochester, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02631733 - Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors | Biotech Hunter | Biotech Hunter